Goldman Sachs Downgrades Forest Laboratories (FRX) to Sell
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Goldman Sachs downgraded Forest Laboratories (NYSE: FRX) from Neutral to Sell with a price target of $33 (down form $35).
The firm said new launches of Viibryd/Daliresp are unlikely to exceed expectations. In addition, the firm sees deceleration for key in-line products (Namenda, Savella), large exclusivity losses (Lexapro, Namenda), and negative operating leverage
For more ratings news on Forest Laboratories click here and for the rating history of Forest Laboratories click here.
Shares of Forest Laboratories closed at $33.18 yesterday.
The firm said new launches of Viibryd/Daliresp are unlikely to exceed expectations. In addition, the firm sees deceleration for key in-line products (Namenda, Savella), large exclusivity losses (Lexapro, Namenda), and negative operating leverage
For more ratings news on Forest Laboratories click here and for the rating history of Forest Laboratories click here.
Shares of Forest Laboratories closed at $33.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
- Berenberg Downgrades PolyPeptide Group AG (PPGN:SW) to Hold
- JPMorgan Downgrades Mereo BipPharma Group (MREO) to Underweight
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
